Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes

Pathobiology

Volumn 75, Issue 3, 2008, Pages 200-208

  Hegde, Upendra ^a   Chhabra, Arvind ^a   Chattopadhyay, Subhasis ^a   Das, Raja ^a   Ray, Swagatam ^a   Chakraborty, Nitya G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cytokine; Cytotoxic T lymphocytes; Melanoma; Peripheral blood lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; MELAN A;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VIDARABINE;

EID: 48749128548     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000124981     Document Type: Article

References (32)

1. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA: A highly immunogenic tumor transfected with a murine transforming growth factor type 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486-1490.
2. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR: Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-272.
3. Beck C, Schreiber H, Rowley D: Role of TGF-β in immune-evasion of cancer. Microsc Res Tech 2001;52:387-395.
4. Salazar-Onfray F: Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol 1999;16:86-94.
5. Takahashi T, Sakaguchi S: Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med 2003;3:693-706.
6. Kuwana M: Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 2002;63:1156-1163.
7. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S, Colonna M, Cortesini R, Dalla-Favera R, Suciu-Foca N: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002;3:237-243.
8. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF: Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-118.
9. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
10. Chattopadhyay S, Chakraborty NG, Mukherji B: Regulatory T cell and tumor immunity. Cancer Immunol Immunother 2005;54:1153-1161.
11. Chattopadhyay S, Mehrotra S, Chhabra A, Hegde U, Mukherji B, Chakraborty NG: Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor associated epitope in vitro. J Immunol 2006;176:984-990.
12. Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B: Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines. J Immunol 1999;162:5576-5583.
13. Chakraborty NG, Chattopadhyay S, Mehorotra S, Chhabra A, Mukherji B: Regulatory T cell response and vaccine induced CTL response in human melanoma. Hum Immunol 2004;65:794-802.
14. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
15. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
16. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186:1213-1221.
17. Dabbagh K, Lewis DB: Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003;16:199-204.
18. Yang Y, Huang CT, Huang X, Pardoll DM: Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5:508-515.
19. Chattopadhyay S, Chakraborty NG: Continuous presence of Th1 conditions are necessary for longer lasting tumor antigen specific CTL activity in stimulation culture with PBL. Hum Immunol 2005;66:884-891.
20. North RJ, Digiacomo A, Dye ES: Suppression of antitumor immunity; in Otter WD, Ruitenberg EJ (eds): Tumor Immunology, Mechanisms, Diagnosis, Therapy. Amsterdam, Elsevier Science Publishers, 1987.
21. Lutsiak Christine ME, Semnani RT, Pascalis RD, Kashmiri SVS, Schlom J, Sabzevani H: Inhibition of CD4+CD25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-2868.
22. Wright SJ, Robertson LE, O'Brian S, Plunkett W and Keating MJ: Role of fludarabine in hematologic malignancies. Blood 1994;8:125-134.
23. Beyer M, Kochanek M, Darabi K, et al: Reduced frequencies and suppressive function of CD4+CD25+ regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-2025.
24. Gamberale R, Galmarini CM, Fernandez-Calotti P, Jordheim L, Sanchez-Avalos J, Dumontet C, Geffner J, Giordano M: In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochem Pharmacol 2003;66:2185-2191.
25. Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B: Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. J Immunol 2004;173:6017-6024.
26. Mehrotra S, Stevens R, Zengou R, Chakraborty NG, Butterfield LH, Economou JS, Dorsky DI, Mukherji B: Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res 2003;63:5607-5614.
27. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barloie B, Valeaquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
28. Young JL Jr, Percy CL, Asire AJ, et al: Cancer incidence and mortality in the United States, 1973-77. Natl Cancer Inst Monogr 1981;57:1-187.
29. O'Brien S, del Giglio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995;85:307-318.
30. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
31. Wendtner CM, Schmitt B, Bergmann M, Rohnisch T, Buhmann R, Hallek M: New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. Int J Hematol 2001;73:32-38.
32. Nishioka C, Ikezoe T, Togitani K, Yokoyama A: Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor κB. Bone Marrow Transplant 2008;41:303-309.